Prostate-specific membrane antigen (PSMA) has become the most important biomarker for prostate cancer diagnosis and therapy, as PSMA has been found to be overexpressed in 95% of PCa tumors, with increasing expression levels in higher-grade and metastatic lesions [1]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.